BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10928056)

  • 1. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
    Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
    Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node-negative primary breast carcinoma.
    Imam SA; Chaiwun B; Wang MJ; Morris MM; Groshen SG; Neville AM; Torloni H; Cote RJ; Taylor CR
    Anticancer Res; 1996; 16(5B):3043-8. PubMed ID: 8920764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
    Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
    Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a cell-surface antigen (LEA.135) associated with favorable prognosis in human breast cancer.
    Imam SA; Esteban EF; Chen RS; Cardiff RD; Taylor CR
    Cancer Res; 1993 Jul; 53(14):3233-6. PubMed ID: 7686814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.
    Liu S; Edgerton SM; Moore DH; Thor AD
    Clin Cancer Res; 2001 Jun; 7(6):1716-23. PubMed ID: 11410511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.